{"url_path":"/sec/rdhl/10-k/2026/item-9","section_key":"item-9","section_title":"Item 9 THE OFFER AND LISTING**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1553846/0001104659-26-049055-index.html","accession_number":"0001104659-26-049055","cik":"0001553846","ticker":"RDHL","issuer_name":"RedHill Biopharma Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1553846/0001104659-26-049055-index.html","primary_entity_key":"0001553846","primary_entity_name":"RedHill Biopharma Ltd."},"word_count":174,"has_tables":true,"body_markdown":"**ITEM 9.         THE OFFER AND LISTING**\n\n**A.****Offer and Listing Details**\n\nOur Ordinary Shares were traded on the TASE under the symbol “RDHL” from February 2011 to February 2020 and were voluntarily delisted from trading on the TASE, effective February 13, 2020. They are listed but are not traded on Nasdaq in connection with the ADSs. The ADSs were traded on Nasdaq under the symbol “RDHL” from December 27, 2012, were listed on the Nasdaq Global Market under the same symbol from July 20, 2018, to November 14, 2023, and have been re-listed on Nasdaq Capital Market under the same symbol since November 15, 2023.\n\n**B.         Plan of Distribution**\n\nNot applicable.\n\n**C.         Markets**\n\nThe ADSs, each representing 10,000 Ordinary Shares and evidenced by an American depositary receipt (“ADRs”), are traded on Nasdaq under the symbol “RDHL.” The ADRs are issued pursuant to a Depositary Agreement entered into with The Bank of New York Mellon.\n\n**D.         Selling Shareholders**\n\nNot applicable.\n\n**E.         Dilution**\n\nNot applicable.\n\n**F.         Expenses of the Issue**\n\nNot applicable.\n\n​\n\n145\n\n[Table of Contents](#TOC)"}